EP PerMed – JTC 2024: European Partnership for Personalised Medicine

With its first joint transnational call, EP PerMed aims to fund research that fosters the identification or validation of targets for personalised medicine (PM) approaches.

Applicants submitting a proposal to this call must combine the research on new and advanced targets with companion biomarker research (companion diagnostics). Consortia are required to be transnational, interdisciplinary and trans-sectoral as well as to clearly outline the PM perspective in the research proposed.

The overall objectives of the JTC2024 are to

• Support research projects in human health aiming at identifying or validating targets for personalised medicine approaches in combination with development of companion biomarkers or other markers to allow for monitoring of treatment outcomes and patient stratification;
• Encourage and enable interdisciplinary collaborations by combining pre-clinical and clinical research in translational projects, and multi-actor research by engaging a range of other relevant disciplines such as bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to empower the implementation of PM; and
• Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.

Funding organisations in Spain: Carlos III Health Institute – Instituto de Salud Carlos III (ISCIII), Departament de Salut – Generalitat de Catalunya & Government of Navarre – Comunidad Foral de Navarra – Gobierno de Navarra

Deadline for pre-proposal submission: 05 March, 2024 (17:00, CET)

Deadline for full-proposal submission: 20 June, 2024 (17:00, CET)